Loading...

InMode Ltd.

INMDNASDAQ
Healthcare
Medical - Devices
$14.81
$0.60(4.22%)

InMode Ltd. (INMD) Financial Performance & Income Statement Overview

Explore the financials of InMode Ltd. (INMD), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-19.76%
19.76%
Operating Income Growth
-42.49%
42.49%
Net Income Growth
-8.41%
8.41%
Operating Cash Flow Growth
-24.97%
24.97%
Operating Margin
28.54%
28.54%
Gross Margin
79.98%
79.98%
Net Profit Margin
44.50%
44.50%
ROE
26.59%
26.59%
ROIC
17.86%
17.86%

InMode Ltd. (INMD) Income Statement & Financial Overview

Access detailed annual and quarterly income data for InMode Ltd. INMD financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$77.87M$97.85M$130.23M$86.45M
Cost of Revenue$16.96M$20.22M$24.05M$17.12M
Gross Profit$60.91M$77.64M$106.18M$69.33M
Gross Profit Ratio$0.78$0.79$0.82$0.80
R&D Expenses$2.90M$2.67M$3.25M$3.70M
SG&A Expenses$42.40M$47.11M$54.66M$47.32M
Operating Expenses$45.29M$49.77M$57.92M$51.02M
Total Costs & Expenses$62.26M$69.99M$81.97M$68.14M
Interest Income$6.86M$0.00$9.92M$8.69M
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$174000.00$248000.00$138000.00$177000.00
EBITDA$15.79M$28.11M$48.40M$18.49M
EBITDA Ratio$0.20$0.29$0.37$0.21
Operating Income$15.62M$27.86M$48.26M$18.31M
Operating Income Ratio$0.20$0.28$0.37$0.21
Other Income/Expenses (Net)$6.86M$4.35M$9.92M$8.69M
Income Before Tax$22.48M$32.21M$58.18M$27.004M
Income Before Tax Ratio$0.29$0.33$0.45$0.31
Income Tax Expense$4.28M-$50.56M$7.19M$3.19M
Net Income$18.20M$82.77M$50.99M$23.82M
Net Income Ratio$0.23$0.85$0.39$0.28
EPS$0.26$1.15$0.66$0.28
Diluted EPS$0.26$1.14$0.65$0.28
Weighted Avg Shares Outstanding$68.76M$71.87M$77.02M$83.88M
Weighted Avg Shares Outstanding (Diluted)$69.44M$72.79M$78.55M$85.89M

Financial performance has remained strong, with revenue growing from $86.45M in Q2 2024 to $77.87M in Q1 2025. Gross profit continued to perform well, with margins at 78% in the latest quarter. Operating income reached $15.62M in Q1 2025, holding a steady 20% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $15.79M. Net income dropped to $18.20M, keeping EPS at $0.26. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;